同时靶向组蛋白甲基转移酶G9a与DNA甲基转移酶1治疗实验性肝细胞癌
在268例人肝细胞癌、154例瘤旁组织和32种肝癌细胞系中检测G9a、DNMT1及UHRF1表达,发现三者显著相关过表达且与不良预后相关。G9a与DNMT1单独药物靶向可协同抑制肝癌细胞生长,先导化合物CM-272可抑制肝癌细胞及LX2细胞增殖、抑制肿瘤生长(尤其HCC+LX2异种移植瘤),并恢复FBP1表达。结论认为联合靶向G9a/DNMT1是肝癌治疗的有前景策略。
要点
- 肝癌中G9a、DNMT1和UHRF1显著相关过表达并与不良预后相关。
- 单独药物靶向G9a与DNMT1可协同抑制肝癌细胞生长。
- CM-272可抑制肝癌与LX2细胞增殖及肿瘤生长,尤其HCC+LX2异种移植瘤。
核心结论
- 联合靶向G9a/DNMT1的化合物如CM-272是肝癌治疗的有前景策略。
- 研究结果也凸显了分化治疗在肝癌中的潜力。
研究设计与样本
- 在人肝细胞癌(n=268)、瘤旁组织(n=154)和肝癌细胞系(n=32)中检测G9a、DNMT1及UHRF1表达。
- 通过药物和遗传学方法评估单独及联合抑制G9a与DNMT1对肝癌细胞生长的影响。
- 在常氧和缺氧条件下、人肝星状细胞和LX2细胞中、以及由肝癌细胞或肝癌+LX2细胞形成的异种移植瘤中检测先导化合物CM-272的活性。
主要发现
- 肝癌中G9a、DNMT1和UHRF1显著且相关地过表达,并与不良预后相关。
- 单独药物靶向G9a和DNMT1可协同抑制肝癌细胞生长。
- CM-272有效降低肝癌细胞和LX2细胞增殖并抑制肿瘤生长,尤其在HCC+LX2异种移植瘤中。
- 机制上,CM-272抑制肝癌细胞对缺氧的代谢适应,并诱导肝癌细胞和纤维化细胞的分化表型。
- CM-272恢复了在肝癌中被表观遗传抑制的代谢抑癌基因果糖-1,6-二磷酸酶(FBP1)的表达。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Epigenetic modifications such as DNA and histone methylation functionally cooperate in fostering tumor growth, including that of hepatocellular carcinoma (HCC). Pharmacological targeting of these mechanisms may open new therapeutic avenues. We aimed to determine the therapeutic efficacy and potential mechanism of action of our dual G9a histone-methyltransferase and DNA-methyltransferase 1 (DNMT1) inhibitor in human HCC cells and their crosstalk with fibrogenic cells. The expression of G9a and DNMT1, along with that of their molecular adaptor ubiquitin-like with PHD and RING finger domains-1 (UHRF1), was measured in human HCCs (n = 268), peritumoral tissues (n = 154), and HCC cell lines (n = 32). We evaluated the effect of individual and combined inhibition of G9a and DNMT1 on HCC cell growth by pharmacological and genetic approaches. The activity of our lead compound, CM-272, was examined in HCC cells under normoxia and hypoxia, human hepatic stellate cells and LX2 cells, and xenograft tumors formed by HCC or combined HCC+LX2 cells. We found a significant and correlative overexpression of G9a, DNMT1, and UHRF1 in HCCs in association with poor prognosis. Independent G9a and DNMT1 pharmacological targeting synergistically inhibited HCC cell growth. CM-272 potently reduced HCC and LX2 cells proliferation and quelled tumor growth, particularly in HCC+LX2 xenografts. Mechanistically, CM-272 inhibited the metabolic adaptation of HCC cells to hypoxia and induced a differentiated phenotype in HCC and fibrogenic cells. The expression of the metabolic tumor suppressor gene fructose-1,6-bisphosphatase (FBP1), epigenetically repressed in HCC, was restored by CM-272. Conclusion: Combined targeting of G9a/DNMT1 with compounds such as CM-272 is a promising strategy for HCC treatment. Our findings also underscore the potential of differentiation therapy in HCC.
引用
- Bárcena-Varela M, Caruso S, Llerena S, et al. Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma. Hepatology. 2019. PMID: 30014490. doi:10.1002/hep.30168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。